MacroGenics, Inc. MGNX
3.74
(0.06)
(1.58%)
as of 25 Sep
- Market cap
- $242.1M
- P/E
- 0.0×
Follow MGNX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(81.13%) | (86.95%) | (140.27%) | (32.61%) | |
| (28.36%) | (28.78%) | (31.80%) | (4.94%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(37.64%) | (41.70%) | (71.74%) | (6.78%) | |
Average Days of Receivables |
225.11 | 1.04 | 24.22 | 287.49 | |
Free Cash Flow per Share |
(2.61) | (1.31) | (1.13) | (1.03) | |
Free Cash Flow |
(164.76) | (82.94) | (71.68) | (65.53) | |
Capital Expenditures |
(2.29) | (1.90) | (1.72) | (1.81) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(76.13%) | (33.01%) | (39.88%) | (29.48%) | |
Accounts Receivable Turnover |
2.88 | 63.13 | 14.98 | 2.34 | |
Accounts Payable Turnover |
5.00 | 10.86 | 9.00 | 0.00 | |
Inventory Turnover |
6.36 | 8.05 | 5.18 | — | |
Average Days of Payables |
69.08 | 26.48 | 31.90 | 0.00 | |
Days of Inventory on Hand |
101.76 | 64.28 | 70.69 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
135.49% | 98.44% | 90.68% | 76.72% | |
Selling, General and Administrative Expense of Revenue |
51.43% | 26.19% | 24.29% | 20.08% | |
Share Based Compensation of Revenue |
20.39% | 9.56% | 7.99% | 5.92% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.14 | 1.09 | 0.99 | 4.37 | |
Depreciation/Fixed assets |
0.45 | 2.63 | 0.43 | 1.49 | |
Capex/Depreciation |
(0.36) | (0.34) | (0.35) | (0.51) | |
Revenue per Share |
1.78 | 2.37 | 2.48 | 2.88 | |
Operating CF per Share |
(2.57) | (1.28) | (1.10) | (1.00) | |
Capex per Share |
(0.04) | (0.03) | (0.03) | (0.03) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(67.60%) | (49.91%) | (44.79%) | (7.97%) |
Columns are period end dates